螺内酯在射血分数保留心衰合并肾功能恶化患者中的研究
在TOPCAT-Americas研究的1767例射血分数保留心衰患者中,螺内酯组肾功能恶化发生率高于安慰剂组(17.8% vs 11.6%,OR 1.66,95%CI 1.27-2.17,P<0.001)。无论治疗分组,肾功能恶化均与主要终点风险增加相关(HR 2.04,95%CI 1.52-2.72,P<0.001)。螺内酯相关肾功能恶化与较低的心血管死亡和全因死亡风险相关(交互P分别为0.003和0.001)。
要点
- 螺内酯增加HFpEF患者肾功能恶化风险,但肾功能恶化后心血管死亡率仍较低。
- 肾功能恶化与主要终点风险增加独立相关,但螺内酯治疗未显著改变此关联。
- 临床中螺内酯相关肾功能恶化不应直接等同于不良预后,需结合临床综合评估。
核心结论
- 在HFpEF患者中,螺内酯增加肾功能恶化风险,但螺内酯相关肾功能恶化与较低的心血管死亡和全因死亡风险相关。
研究设计与样本
- TOPCAT-Americas随机对照试验的事后分析,纳入1767例射血分数保留心衰患者,随机分配至螺内酯或安慰剂组。
主要发现
- 肾功能恶化(血清肌酐翻倍)发生于260例(14.7%)患者,螺内酯组发生率17.8%高于安慰剂组11.6%(OR 1.66,95%CI 1.27-2.17,P<0.001)。
- 无论治疗分组,肾功能恶化均与主要终点风险增加相关(HR 2.04,95%CI 1.52-2.72,P<0.001)。
- 治疗分组与肾功能恶化对主要终点的交互作用无统计学意义(交互P=0.11)。
- 螺内酯相关肾功能恶化与安慰剂相关肾功能恶化相比,心血管死亡风险更低(交互P=0.003),全因死亡风险更低(交互P=0.001)。
临床怎么用
- 对于HFpEF患者使用螺内酯期间出现肾功能恶化,不应简单视为停药指征,需结合心血管获益综合评估。
局限性
- 本研究为TOPCAT-Americas的事后分析,结果需在更广泛人群中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment of heart failure with preserved ejection fraction (HFpEF) with spironolactone is associated with lower risk of heart failure hospitalization (HFH) but increased risk of worsening renal function (WRF). The prognostic implications of spironolactone-associated WRF in HFpEF patients are not well understood. OBJECTIVES: The purpose of this study was to investigate the association between WRF, spironolactone treatment, and clinical outcomes in patients with HFpEF. METHODS: In 1,767 patients randomized to spironolactone or placebo in the TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial)-Americas study, we examined the incidence of WRF (doubling of serum creatinine) by treatment assignment. Associations between incident WRF and subsequent risk for the primary study endpoint of cardiovascular (CV) death, HFH, or aborted cardiac arrest and key secondary outcomes, including CV death, HFH, and all-cause mortality according to treatment assignment, were examined in time-updated Cox proportional hazards models with an interaction term. RESULTS: WRF developed in 260 (14.7%) patients with higher rates in those assigned to spironolactone compared to placebo (17.8% vs. 11.6%; odds ratio: 1.66; 95% confidence interval: 1.27 to 2.17; p < 0.001). Regardless of treatment, incident WRF was associated with increased risk for the primary endpoint (hazard ratio: 2.04; 95% confidence interval: 1.52 to 2.72; p < 0.001) after multivariable adjustment. Although there was no statistical interaction between treatment assignment and WRF regarding the primary endpoint (interaction p = 0.11), spironolactone-associated WRF was associated with lower risk of CV death (interaction p = 0.003) and all-cause mortality (interaction p = 0.001) compared with placebo-associated WRF. CONCLUSIONS: Among HFpEF patients enrolled in TOPCAT-Americas, spironolactone increased risk of WRF compared with placebo. Rates of CV death were lower with spironolactone in both patients with and without WRF.
引用
- Beldhuis IE, Myhre PL, Bristow M, et al. Spironolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal Function. J Am Coll Cardiol. 2021. PMID: 33663739. doi:10.1016/j.jacc.2020.12.057
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。